Mostrando 10 resultados de: 15
Filtros aplicados
Área temáticas
Farmacología y terapéutica(11)
Enfermedades(8)
Fisiología humana(5)
Bioquímica(4)
Medicina y salud(4)
CYP2D6 and the severity of suicide attempts
ArticleAbstract: Aim: Among people who die by suicide, an increased frequency of CYP2D6 active gene multiplication haPalabras claves:CYP2D6, severity of suicide attempt, ultrarapid metabolizerAutores:Adrián LLerena, Baca-Garca E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
ArticleAbstract: Aim: In previous CYP2D6 genotyping studies in Mexican-Amerindians a very low frequency of poor metabPalabras claves:CYP2D6, Lacandones, Mexican-Mestizo, pharmacogeneticsAutores:Adrián LLerena, Alonso E., Dorado P., López-López M., Ochoa-Morales A., Ortega A., Penãs-Lledó E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
ArticleAbstract: Background & aim: The CYP2D6-1584C>G polymorphism (rs1080985) has been identified as a major factorPalabras claves:1584C>G, CYP2D6, debrisoquine, Healthy volunteers, ultrarapid metabolismAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusAllele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
ArticleAbstract: Aim: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy iPalabras claves:ABCC2, anti-epileptics, CYP3A5, EPHX1, GABRA1, HNF4A, Mexican-Mestizo, NR1I2, pharmacogenetics, RALBP1, SCN1A, SCN2A, UGT1A1, UGT2B7Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusRelation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers
Conference ObjectAbstract: Aims: A lower serotonin/higher dopamine tone in CYP2D6 poor metabolizers (PMs) versus extensive metaPalabras claves:CANTAB®, CYP2D6, Impulsivity, KSP, personality, pharmacogenetics, Pharmacogenomics, SCL-90-R, TCI-RAutores:Adrián LLerena, Dorado P., González I., Pacheco R., Penãs-Lledó E.M.Fuentes:scopusRelation between CYP2D6 phenotype and genotype and personality in healthy volunteers
ArticleAbstract: Objectives: Our group has previously show that interindividual variability in CYP2D6 hydroxylation cPalabras claves:anxiety, CYP2D6, debrisoquine, KSP, personality, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Alvárez M., Dorado P., González I., Penãs-Lledó E.M., Pérez B.Fuentes:scopusRelationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers
ArticleAbstract: Aim: The CYP2C9 IVS8-109T allele was recently found to be more frequent among Swedish individuals, wPalabras claves:CYP2C9, intronic polymorphism, IVS8-109A>T, LOSARTÁNAutores:Adrián LLerena, Dorado P., Enrique Terán, Gallego A., Penãs-Lledó E.M.Fuentes:googlescopusRelevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients
Conference ObjectAbstract: Aims: The CYP2D6 -1584C>G (rs1080985) polymorphism has been identified as another major factor for CPalabras claves:Antipsychotic drugs, CYP2D6, Mesoridazine, Phenotiazines, ThioridazineAutores:Adrián LLerena, De la Rubia A., Dorado P., Penãs-Lledó E.M.Fuentes:scopusRelevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital
ArticleAbstract: Aim: We evaluated the potential influence of genetic (CYP3A5, EPHX1, NR1I2, HNF4A, ABCC2, RALBP1, SCPalabras claves:ABCC2, carbamazepine, EPHX1, Epilepsy, NR1I2, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopus